Bioxyne (ASX:BXN), through its Breathe Life Sciences subsidiary, fulfilled two standing purchase orders for the supply of BLSMD40 Good Manufacturing Practice-Manufactured MDMA capsules, according to a Tuesday filing with the Australian bourse.
BLSMD40 is an investigational medicine designed to treat post-traumatic stress disorder supplied through Australia's Authorized Prescriber pathway for MDMA-assisted therapy, the filing said.
The capsules are supplied for clinical trials in Victoria and authorized prescribers delivering psychedelic therapy-assisted services in Queensland, per the filing.